Cook D, De Jonghe B, Brochard L, Brun-Buisson C
Department of Medicine, St Joseph's Hospital and McMaster University, Hamilton, Ontario, Canada.
JAMA. 1998 Mar 11;279(10):781-7. doi: 10.1001/jama.279.10.781.
Ventilator-associated pneumonia (VAP) is a serious complication of critical illness, conferring increased morbidity and mortality. Many interventions have been studied to reduce the risk of VAP. We systematically reviewed the influence of airway management on VAP in critically ill patients.
Studies were identified through searching MEDLINE and EMBASE from 1980 through July 1997 and by searching SCISEARCH, the Cochrane Library, bibliographies of primary and review articles, personal files, and contact with authors of the randomized trials.
We selected randomized trials evaluating ventilator circuit and secretion management strategies on the rate of VAP.
Two investigators independently abstracted key data on design features, the population, intervention, and outcome of the studies.
The frequency of ventilator circuit changes and the type of endotracheal suction system do not appear to influence VAP rates (3 trials, none with significant difference; range of relative risks [RRs], 0.84-0.91). However, lower VAP rates may be associated with avoidance of heated humidifiers and use of heat and moisture exchangers (5 trials, only 1 showing a significant difference; range of RRs, 0.34-0.86), use of oral vs nasal intubation (1 trial; RR, 0.52; 95% confidence interval, 0.24-1.13), subglottic secretion drainage vs standard endotracheal tubes (2 trials, 1 showing a significant difference; range of RRs, 0.46-0.57), and kinetic vs conventional beds (5 trials, only 1 showing a significant difference; range of RRs, 0.35-0.78).
Some ventilator circuit and secretion management strategies may influence VAP rates in critically ill patients. Whether these strategies are adopted in practice depends on several factors such as the magnitude and precision of estimates of benefit and harm, as well as access, availability, and costs.
呼吸机相关性肺炎(VAP)是危重症的一种严重并发症,会增加发病率和死亡率。已经对许多干预措施进行了研究,以降低VAP的风险。我们系统评价了气道管理对危重症患者VAP的影响。
通过检索1980年至1997年7月的MEDLINE和EMBASE,以及检索SCISEARCH、Cochrane图书馆、原始文章和综述文章的参考文献、个人档案并与随机试验的作者联系来确定研究。
我们选择了评估呼吸机回路和分泌物管理策略对VAP发生率影响的随机试验。
两名研究人员独立提取有关研究设计特点、研究对象、干预措施和结果的关键数据。
呼吸机回路更换的频率和气管内吸引系统的类型似乎不影响VAP发生率(3项试验,均无显著差异;相对危险度[RRs]范围为0.84 - 0.91)。然而,较低的VAP发生率可能与避免使用加热湿化器和使用热湿交换器有关(5项试验,只有1项显示有显著差异;RRs范围为0.34 - 0.86),使用经口插管与经鼻插管(1项试验;RR为0.52;95%置信区间为0.24 - 1.13),声门下分泌物引流与标准气管内导管(2项试验,1项显示有显著差异;RRs范围为0.46 - 0.57),以及动力床与传统床(5项试验,只有1项显示有显著差异;RRs范围为0.35 - 0.78)。
一些呼吸机回路和分泌物管理策略可能会影响危重症患者的VAP发生率。这些策略在实际中是否采用取决于几个因素,如利弊估计的幅度和精确度,以及可及性、可用性和成本。